On May 4, 2021, Amgen Canada announced the launch of their adalimumab biosimilar AMGEVITA (reference drug HUMIRA) for the treatment of 11 chronic inflammatory conditions. AMGEVITA is available as a prefilled syringe and a prefilled pen (SureClick® autoinjector) with a range of pack sizes to support dosing according to the approved dosage recommendations in each indication. AMGEVITA is also provided in a citrate-free formulation.
Suna Avcil, executive medical director of Amgen Canada, stated “We are pleased that AMGEVITA is now available in Canada, offering patients and physicians a treatment option and flexibility of choice in therapies they may not otherwise have.”